Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GLOBUS MEDICAL INCGMED · Entity 3496 | EVP, International Sales | February 02, 2018 | February 06, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GLOBUS MEDICAL INC
Report date February 02, 2018 · Filed February 06, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy Class A Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $45.64 · Expires 2028-02-02 | Direct | 40,000 |
Reported balance
After 2018-02-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-02-02 · Grant · Acquired 40,000 · Balance 40,000 F1: These options were granted on February 2, 2018, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2019, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months. |
Filing footnotes · ownership attribution and instrument terms
F1: These options were granted on February 2, 2018, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2019, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 02, 2018 Filed Feb 6, 2018 21:02 UTC | GLOBUS MEDICAL INC GMED · Entity 3496 | GrantStock Option (Right to Buy Class A Common Stock) · Derivative | 40,000 | $0.00 Strike: $45.64 | $0.00 |
DisclosureSEC source: 0001209191-18-007824 · doc4.xml · derivative · entry 1 Murphy A Brett · CIK 0001555034 · EVP, International Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Class A Common Stock · 40,000 shares Expires 2028-02-02 F1 · derivative.exercise_date: These options were granted on February 2, 2018, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2019, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months. Read SEC document |
| November 10, 2017 Filed Nov 13, 2017 21:10 UTC | GLOBUS MEDICAL INC GMED · Entity 3496 | SaleClass A Common Stock | 14,551 | $35.00 | $509,285.00 |
DisclosureSEC source: 0001209191-17-060278 · doc4.xml · nonDerivative · entry 2 Murphy A Brett · CIK 0001555034 · Group President, Commerical Op 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,217 F1 · kind: This sale was pursuant to a Rule 10b5-1 Plan entered into by the reporting person on May 20, 2017, which is intended to comply with Rule 10b5-1. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 21:10 UTC | GLOBUS MEDICAL INC GMED · Entity 3496 | SaleClass A Common Stock | 51,449 | $35.00 | $1,800,715.00 |
DisclosureSEC source: 0001209191-17-060278 · doc4.xml · nonDerivative · entry 1 Murphy A Brett · CIK 0001555034 · Group President, Commerical Op 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,768 F1 · kind: This sale was pursuant to a Rule 10b5-1 Plan entered into by the reporting person on May 20, 2017, which is intended to comply with Rule 10b5-1. Read SEC document |
| September 06, 2017 Filed Sep 7, 2017 20:05 UTC | GLOBUS MEDICAL INC GMED · Entity 3496 | SaleClass A Common Stock | 15,000 | $29.99 | $449,902.50 |
DisclosureSEC source: 0001209191-17-051867 · doc4.xml · nonDerivative · entry 1 Murphy A Brett · CIK 0001555034 · President, Commerical Op 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,217 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.975 to $30.015, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| January 30, 2017 Filed Feb 1, 2017 21:04 UTC | GLOBUS MEDICAL INC GMED · Entity 3496 | GrantStock Option (Right to Buy Class A Common Stock) · Derivative | 80,000 | $0.00 Strike: $26.27 | $0.00 |
DisclosureSEC source: 0001209191-17-006653 · doc4.xml · derivative · entry 1 Murphy A Brett · CIK 0001555034 · President, Commerical Op 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Class A Common Stock · 80,000 shares Expires 2027-01-30 F1 · derivative.exercise_date: These options were granted on January 30, 2017, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2018, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.